Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evolocumab for prevention of cardiovascular events in high-risk patients without prior myocardial infarction or stroke
CTR20191381Phase 3Terminated
- Sponsor
- Amgen
- Start
- Mar 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of evolocumab in atherosclerotic disease, coronary arteriosclerosis, cerebrovascular disease, arteriosclerosis obliterans, type 2 diabetes mellitus (T2DM), sponsored by Amgen. Started Mar 2020; status: terminated.
02
Drugs
evolocumab
03
Conditions
atherosclerotic diseasecoronary arteriosclerosiscerebrovascular diseasearteriosclerosis obliteranstype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on CTR20191381.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20191381.